MATRIX METALLOPROTEINASE-9 AND INFLAMMATION IN DIFFERENT TYPES OF MULTIPLE SCLEROSIS

Nataliya Voloshyna, Vitaliy Vasylovskyy, Tatyana Nehreba, Maksym Chernenko, Viktoriya Vovk

Abstract


Different clinical courses of multiple sclerosis, heterogeneity of its clinical implications, different effect of immunomodulatory therapy for the same clinical forms implies various pathogenetic mechanisms of central nervous system damage at this disease. Applicability of immunological and biochemical markers for the estimation of immunocorrecting and anti-inflammatory therapy efficacy is important. This research aims at improvement of pathological process stages diagnostics at multiple sclerosis and further therapy optimization depending on the activity of the inflammatory process. In the article matrix metalloproteinase-9 rate was assessed in 135 patients with multiple sclerosis of different course types and at different activity stages of the pathological process. The highest matrix metalloproteinase-9 rates were in patients with relapsing-remitting type at the stage of exacerbation, with the lowest rate being in patients with primary-progressive multiple sclerosis. Determination of matrix metalloproteinase-9 rate allows to assess the degree of inflammatory process expression and to monitor the efficacy of multiple sclerosis treatment.

Keywords


multiple sclerosis; matrix metalloproteinase-9; relapsing-remitting course type; progressive course type

Full Text:

PDF FIGURES TABLES

References


Gusev, Ie. I., Boiko, A. N. (2001). Multiple Sclerosis: From Immunopathogenesis Studies to New Treatment Methods. Moscow: Gubernskaya meditsina, 101.

Kicherova, О. А., Reichart, L. I., Bychenko, S. M. (2007). Multiple sclerosis. Tyumen: City-press, 152.

Trapp, B. D., K. A. Nave. (2008). Multiple sclerosis: an immune or neuro-degenerative disorder? Annual Review of Neuroscience, 31 (1), 247–269. doi: 10.1146/annurev.neuro.30.051606.094313

McFarland, H. F., Martin, R. (2007). Multiple sclerosis: a complicated picture of autoimmunity. Nature Immunology, 8 (9), 913–919. doi: 10.1038/ni1507

Lucchinetti, C. F. B., Popescu, F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W. (2012). Inflammatory Cortical Demyelination in Early Multiple Sclerosis. The Lancet neurol., 1 (34), 6.

Man, S, Ubogu, E. E., Ransohoff, R. M. (2007). Inflammatory cell migration into the central nervous system: a few new twists on the old tale. Brain Pathology, 17 (2), 243–250. doi: 10.1111/j.1750-3639.2007.00067.x

Cox, M. B., Bowden, N. A., Scott, R. J., Lechner-Scott, J. (2013). Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation. Multiple Sclerosis Journal, 19 (10), 1268–1274. doi: 10.1177/1352458513475493

Nag, S. (2011). The Blood-Brain Barrier: Biology and Research Protocols. Springer, Methods in Molecular Biology, 686. doi: 10.1007/978-1-60761-938-3

Ichiyama, T., Kajimoto, M., Suenaga, N., Maeba, S., Matsubara, T., Furukawa, S. (2006). Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. Journal of Neuroimmunology, 172 (1-2), 182–186. doi: 10.1016/j.jneuroim.2005.10.010

Yong, V. W., Zabad, R. K., Agrawal, S., Goncalves Dasilva, A., Metz, L. M. (2007). Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immuno-modulators. Journal of the Neurological Sciences, 259 (1-2), 79–84. doi: 10.1016/j.jns.2006.11.021

Trentini, A., Manfrinato, M. C., Castellazzi, M., Tamborino, C., Roversi, G. et. al. (2015). TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. Multiple Sclerosis Journal, 21 (9), 1121–1130. doi: 10.1177/1352458514560925

Benesová, Y., Vasku, A., Novotná, H., Litzman, J., Stourac, P., Beránek, M., Kadanka, Z., Bednarík, J. (2009). Matrix metallo-proteinase-9 and matrix metalloproteinase-2 as bi-omarkers of various courses in multiple sclerosis. Multiple Sclerosis, 15 (3), 316–322. doi: 10.1177/1352458508099482

Gijebels, K., Galadry, R. E., Steinman, L. (2011). Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. Journal of Clinical Investigation, 94 (6), 2177–2182. doi: 10.1172/jci117578

Waubant, E., Goodkin, D., Gee, L., Bacchetti, P., Sloan, R. et al. (1999). Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology, 53 (7), 1397–1401. doi: 10.1212/wnl.53.7.1397

Abraham, M., Shapiro, S., Karni, A., Weiner HL, Miller A. (2005). Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Thl vs. Th2 cells. J Neuroimmunol., 163 (1-2), 157–164.

Amalinei, C., Caruntu, I. D., Giusça, S. E., Balan, R. A. (2010). Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol, 51, 215–228.

Hohlfeld, R. (2007). Does inflammation stimulate remyelination? Journal of Neurology, 254 (1), 147–154. doi: 10.1007/s00415-007-1009-6

Fernandes, K. S., Brum, D. G., Palei, A. C., Sandrim, V. C., Guerreiro, C. T. et al. (2012). Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients. Journal of Neuroimmunology, 249 (1-2), 56–59. doi: 10.1016/j.jneuroim.2012.04.001

Rossano, R., Larocca, M., Riviello, L., Coniglio, M. G., Vandooren, J. et al. (2014). Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants. Journal of Cellular and Molecular Medicine, 18 (2), 242–252. doi: 10.1111/jcmm.12181

Hohlfeld, R., Kerschensteiner, M., Meinl, E. (2007). Dual role of inflammation in CNS disease. Neurology, 68 (22), 58–63. doi: 10.1212/01.wnl.0000275234.43506.9b

Yong, V. W. (2005). Metalloproteinases: mediators of pathology and regeneration in the CNS. Nature Reviews Neuroscience, 6 (12), 931–944.

Verslegers, M., Lemmens, K., Van Hove, I., Moons, L. (2013). Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Progress in Neurobiology, 105, 60–78. doi: 10.1016/j.pneurobio.2013.03.004

Szklarczyk, A., Conant, K. (2010). Matrix Metalloproteinases, Synaptic Injury, and Multiple Sclerosis. Frontiers in Psychiatry, 1, 130. doi: 10.3389/fpsyt.2010.00130




DOI: http://dx.doi.org/10.21303/2504-5679.2016.00039

Refbacks

  • There are currently no refbacks.


Bookmark and Share


Copyright (c) 2016 Nataliya Voloshyna, Vitaliy Vasylovskyy, Tatyana Nehreba, Maksym Chernenko, Viktoriya Vovk

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)